<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02837939</url>
  </required_header>
  <id_info>
    <org_study_id>IMUNO - HEGITO 7</org_study_id>
    <nct_id>NCT02837939</nct_id>
  </id_info>
  <brief_title>Transfer Factor Efficacy in the Management of Cirrhosis-associated Immune Dysfunction</brief_title>
  <acronym>IMUNO-HEGITO7</acronym>
  <official_title>Prospective Randomized Single-blind Study on Transfer-factor in Acute Decompensation of Advanced Chronic Liver Disease and Acute-on-chronic Liver Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin Janičko</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pavol Jozef Safarik University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to assess the efficacy of Human derived Transfer factor ( T-lymphocytes&#xD;
      homogenate that contains small molecular weight (10 kDa) molecules: various IFNs, ILs,&#xD;
      chemokines, endorfins, heat shock proteins) in decreasing rate and/or severity of infections&#xD;
      in acute or chronic decompensations of liver cirrhosis and acute on chronic liver failure..&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most of mortality from advanced chronic liver disease (ACLD) is mediated by so- called&#xD;
      specific complications of end-stage liver disease (ESLD); one of the most important is&#xD;
      infection (25-30%). Infection is responsible for considerable proportion of ESLD-related&#xD;
      mortality. Important in pathogenesis of infections in ESLD is CAIDS (cirrhosis - associated&#xD;
      immune dysfunction syndrome), recently re-named to CAID (Cirrhosis-Associated Immune&#xD;
      Deficit). TRANSFER FACTOR (TF) is supposed to act at several points in CAID - cascade. This&#xD;
      gave rise to hypothesis, that TF could be of benefit in AD/ACLF.&#xD;
&#xD;
      Characteristics of TF It has been shown that transmission fo T-Lymphocyte reactivity is&#xD;
      transmissible not only by T-cells alone, but also by hommogenate of peripheral white blood&#xD;
      cells. Later it became clear that for the transmission of cellular immunity is responsible&#xD;
      dialysable fraction of T-lymphocytes homogenate (with small molecular weight of 10 kDa;&#xD;
      consists of amino acids, small peptides, nucleotides etc). This homogenate was named Transfer&#xD;
      - factor (TF). One dose of lyophilized drug contains: Leucocyti dialysatum 200 x 10 6&#xD;
      (contains various IFNs, ILs, chemokines, endorfins, heat shock protein etc)&#xD;
&#xD;
        -  stimulates T H 1 response&#xD;
&#xD;
        -  induces production of IL-1, IL-2&#xD;
&#xD;
        -  activates chemotaxis of immunocompetent cells&#xD;
&#xD;
        -  increases fagocytic activity&#xD;
&#xD;
        -  activates antigen-presentation by APCs&#xD;
&#xD;
      The aim of this study is to assess the efficacy of transfer factor in decreasing rate and/or&#xD;
      severity of infections in ACLF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoint that includes the incidence specified infections:</measure>
    <time_frame>Two years</time_frame>
    <description>Spontaneous bacterial peritonitis&#xD;
Urinary tract infections:&#xD;
Pneumonia&#xD;
Skin and soft tissue infections&#xD;
Spontaneous bacteremia&#xD;
Endocarditis&#xD;
Tuberculosis&#xD;
Infectious colitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Two years</time_frame>
    <description>The length of hospital stay after the admission with diagnosed infection or contraction of infection during hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The usage of antibiotics required for treatment of a diagnosed infection</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse effects</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in the phagocytic activity of macrophages</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in the levels of imunoglobulins IgA, IgG, IgM, IgD, IgE</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in the capacity for oxidative burst in macrophages</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in the complement levels and activation pathways activity</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in lymphocyte subpopulations</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in the levels of immunomodulators - IL-6, TNF alpha</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Liver Failure</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Human derived Transfer factor applied by subcutaneous injection in specified time points.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aqua pro injectione 4 mL ampules for subcutaneous administration in the same time points as in the active arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human derived Transfer factor</intervention_name>
    <description>One dose (the content of one amp.) of lyophilised drug contains:&#xD;
Leucocyte dialysatum 200 x 10 to the power of 6 (Lyophilized dialysate from 200 million leukocytes) pH = 7.8 to 9 after reconstitution (dissolving) of drug&#xD;
To be administered subcutaneously as follows:&#xD;
12 doses TF in total:&#xD;
3 x TF in first week: day 1,3,5&#xD;
2 x TF in week 2: day 8 , 11&#xD;
1 xTF in week 3 and 4 : day 15, 22&#xD;
1 x TF once a month up to 6 month</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>IMMODIN. Holder: IMUNA PHARM a.s. - GRIFOLS (SVK) Registration number: 59/0147/89-CS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aqua pro injectione 4ml ampules for subcutaneous injection</intervention_name>
    <description>12 doses in total:&#xD;
3 doses in first week: day 1,3,5&#xD;
2 doses in week 2: day 8 , 11&#xD;
1 dose in week 3 and 4 : day 15, 22&#xD;
1 dose once a month up to 6 month</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  admission to hospital at participating liver units or ICUs or internal medicine wards&#xD;
             with acute decompensation (AD) of advanced chronic liver disease or acute-on-chronic&#xD;
             liver failure according to CLIF - C criteria&#xD;
&#xD;
          -  ability to provide informed consent,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  disapproval&#xD;
&#xD;
          -  lymphoproliferative disorders&#xD;
&#xD;
          -  liver transplantation in the past&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  suspected. chronic infection in risk locations&#xD;
&#xD;
          -  CNS&#xD;
&#xD;
          -  peritoneum&#xD;
&#xD;
          -  Known virus-related immune deficiency&#xD;
&#xD;
          -  malignancy&#xD;
&#xD;
          -  severe heart failure (NYHA &gt;= III)&#xD;
&#xD;
          -  severe lung disease (COPD, GOLD&gt;3)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lubomir Skladany, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>F.D.Roosevelt Teaching Hospital with policlinic, Banska Bystrica, Slovakia, 97517</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lubomir Skladany, MD, PhD</last_name>
    <phone>+421484412135</phone>
    <email>lubomir.skladany@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jana Vnencakova, PhDr</last_name>
    <phone>+421484412685</phone>
    <email>jvnencakova@nspbb.sk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>F.D.Roosevelt Teaching Hospital with policlinic Banska Bystrica</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97517</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana Adamcova Selcanova, MD</last_name>
      <phone>+42148441</phone>
      <phone_ext>2135</phone_ext>
      <email>hepato@nspbb.sk</email>
    </contact>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Pavol Jozef Safarik University</investigator_affiliation>
    <investigator_full_name>Martin Janičko</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine, Faculty of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

